Newsfeed

Bei diesem Bereich handelt es sich um eine mögliche Darstellungsform der Integration von Nachrichtenquellen mit Bezug zu börsennotierten Unternehmen.
Als Präsentationsebene fungiert ein Template, dass an Kurznachrichtenservices angelehnt ist, bei dem sich Nutzer einen schnellen Überblick über aktuelle Nachrichten verschaffen können. Die Detailansichten ermöglichen bei Interesse weitergehende Recherchen.

Dieser Newsfeed ist eine Zusammenstellung aktueller Nachrichten, die aus Direktanbindungen von TopTier NewsWire-Services mit Bezug zu börsennotierten Unternehmen stammen. Dieser Feed hier dient ausschließlich Demonstrationszwecken. Sektoren-spezifische Nachrichten, Public Relations sowie Produktinformationen können über die GICS Portale > Bereich Sektor-Intelligence abgerufen werden.

US85209E2081
Filter zurücksetzen
Do you already know our new terminal view? Click here.
FIGI: BBG00HYZ1522
SPRBSPRB
Spruce Biosciences, Inc
GICS: Health Care · SECTOR: EQTY · SUB-SECTOR: - · THEMEFOLIO: $HLTH
NAME
Spruce Biosciences, Inc
ISIN
US85209E2081
TICKER
SPRBSPRB
MIC
XNAS
REUTERS
SPRB.OQ
BLOOMBERG
SPRB US
Mo., 24.08.2026       Spruce Biosciences
US85209E2081

Spruce Biosciences, Inc. (Nasdaq: SPRB) (“Spruce”), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for neurological disorders with significant unmet medical need, today announced that it has completed two pre-BLA meetings with the U.S. Food and Drug Administration (FDA) that support the company's p...
Zur Nachricht
Spruce Biosciences
Charts & Research Termsheets Terminal
Permalink
Mi., 12.08.2026       Spruce Biosciences
US85209E2081

Spruce Biosciences, Inc. (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for neurological disorders with significant unmet medical need, today reported financial results for the second quarter ended June 30, 2026, and provided corporate updates. “The second quarter was a period of...
Zur Nachricht
Spruce Biosciences
Charts & Research Termsheets Terminal
Permalink
Mi., 12.08.2026       Spruce Biosciences
US85209E2081

Spruce Biosciences, Inc. (Nasdaq: SPRB) a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for neurological disorders with significant unmet medical need, today announced that Cure Sanfilippo Foundation and the National MPS Society have agreed to make a combined $5.5 million strategic investment in Spr...
Zur Nachricht
Spruce Biosciences
Charts & Research Termsheets Terminal
Permalink
Mo., 03.08.2026       Spruce Biosciences
US85209E2081

Spruce Biosciences, Inc. (“Spruce Biosciences” or “Spruce”) (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for neurological disorders with significant unmet medical need, today announced the appointment of Jessica Cohen Pfeffer, M.D., as Vice President, Clinical Development, effectiv...
Zur Nachricht
Spruce Biosciences
Charts & Research Termsheets Terminal
Permalink
Mo., 27.07.2026       Spruce Biosciences
US85209E2081

Spruce Biosciences, Inc. (“Spruce Biosciences” or “Spruce”) (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for neurological disorders with significant unmet medical need, today announced the appointment of Adrian Quartel, M.D., FFPM, as Chief Medical Officer, effective today. Dr. Qua...
Zur Nachricht
Spruce Biosciences
Charts & Research Termsheets Terminal
Permalink
Mo., 29.06.2026       Spruce Biosciences
US85209E2081

Spruce Biosciences, Inc. (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for neurological disorders with significant unmet medical need, today announced that it has been added as a member of the Russell 3000® Index, effective with the opening of U.S. equity markets today, in connecti...
Zur Nachricht
Spruce Biosciences
Charts & Research Termsheets Terminal
Permalink
Mo., 22.06.2026       Spruce Biosciences
US85209E2081

Spruce Biosciences, Inc. (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for neurological disorders with significant unmet medical need, today announced the appointment of Agnieszka “AJ” Jurecka, M.D., Ph.D., MPH, as Vice President, Medical Affairs. “We are delighted to welcome AJ...
Zur Nachricht
Spruce Biosciences
Charts & Research Termsheets Terminal
Permalink
Mo., 15.06.2026       Spruce Biosciences
US85209E2081

Spruce Biosciences, Inc. (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for neurological disorders with significant unmet medical need, today announced the appointments of Eric Jordan as Vice President, Marketing and Tina Gullotta, CPA, as Vice President, Finance and Corporate Contro...
Zur Nachricht
Spruce Biosciences
Charts & Research Termsheets Terminal
Permalink
Mo., 08.06.2026       Spruce Biosciences
US85209E2081

Spruce Biosciences, Inc. (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for neurological disorders with significant unmet medical need, today announced that data demonstrating the long-term benefit of tralesinidase alfa enzyme replacement therapy (TA-ERT) in patients with Sanfilippo...
Zur Nachricht
Spruce Biosciences
Charts & Research Termsheets Terminal
Permalink
Do., 28.05.2026       Spruce Biosciences
US85209E2081

Spruce Biosciences, Inc. (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for neurological disorders with significant unmet medical need, today announced that data on the long-term administration of its tralesinidase alfa enzyme replacement therapy (TA-ERT) for the treatment of Sanfil...
Zur Nachricht
Spruce Biosciences
Charts & Research Termsheets Terminal
Permalink
Silent Ad
Mi., 27.05.2026       Spruce Biosciences
US85209E2081

Spruce Biosciences, Inc. (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for neurological disorders with significant unmet medical need, today announced that members of the management team will present and participate in one-on-one meetings at upcoming conferences taking place in Jun...
Zur Nachricht
Spruce Biosciences
Charts & Research Termsheets Terminal
Permalink
Mi., 13.05.2026       Spruce Biosciences
US85209E2081

Spruce Biosciences, Inc. (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for neurological disorders with significant unmet medical need, today reported financial results for the first quarter ended March 31, 2026 and provided corporate updates. “We are very pleased with the meaning...
Zur Nachricht
Spruce Biosciences
Charts & Research Termsheets Terminal
Permalink
Mo., 04.05.2026       Spruce Biosciences
US85209E2081

Spruce Biosciences, Inc. (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for neurological disorders with significant unmet medical need, today announced the appointments of Brian Walls as Vice President, Market Access and Darren M. Johnson as Vice President, Commercial Operations....
Zur Nachricht
Spruce Biosciences
Charts & Research Termsheets Terminal
Permalink
Di., 21.04.2026       Spruce Biosciences
US85209E2081

Spruce Biosciences, Inc. (“Spruce Biosciences”) (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for neurological disorders with significant unmet medical need, today announced the pricing of its previously announced underwritten public offering of 1,150,000 shares of its common stock...
Zur Nachricht
Spruce Biosciences
Charts & Research Termsheets Terminal
Permalink
Mo., 20.04.2026       Spruce Biosciences
US85209E2081

Spruce Biosciences, Inc. (“Spruce Biosciences”) (NASDAQ: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for neurological disorders with significant unmet medical need, today announced that it has commenced an underwritten public offering of shares of its common stock or pre-funded warrants t...
Zur Nachricht
Spruce Biosciences
Charts & Research Termsheets Terminal
Permalink
Mo., 09.03.2026       Spruce Biosciences
US85209E2081

Spruce Biosciences, Inc. (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for neurological disorders with significant unmet medical need, today reported financial results for the year ended December 31, 2025 and provided corporate updates. “2025 was a very productive year, and our t...
Zur Nachricht
Spruce Biosciences
Charts & Research Termsheets Terminal
Permalink
Mo., 09.03.2026       Spruce Biosciences
US85209E2081

Spruce Biosciences, Inc. (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for neurological disorders with significant unmet medical need, today announced the appointment of Dale Hooks as Chief Commercial Officer. Mr. Hooks joins the company with nearly 35 years of pharmaceutical mar...
Zur Nachricht
Spruce Biosciences
Charts & Research Termsheets Terminal
Permalink
Mo., 02.03.2026       Spruce Biosciences
US85209E2081

Spruce Biosciences, Inc. (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for neurological disorders with significant unmet medical need, today announced that Javier Szwarcberg, M.D., M.P.H., Chief Executive Officer, will present at two upcoming investor conferences taking place in Ma...
Zur Nachricht
Spruce Biosciences
Charts & Research Termsheets Terminal
Permalink
Mi., 08.10.2025       Spruce Biosciences
US85209E2081

Spruce Biosciences, Inc. (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for neurological disorders with significant unmet medical need, today announced that it has entered into a definitive securities purchase agreement for a private placement that is expected to result in gross pro...
Zur Nachricht
Spruce Biosciences
Charts & Research Termsheets Terminal
Permalink
Mo., 06.10.2025       Spruce Biosciences
US85209E2081

Spruce Biosciences, Inc. (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for neurological disorders with significant unmet medical need, today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation (BTD) to tralesinidase alfa enzyme re...
Zur Nachricht
Spruce Biosciences
Charts & Research Termsheets Terminal
Permalink
Silent Ad
Mo., 15.09.2025       Spruce Biosciences
US85209E2081

Spruce Biosciences, Inc. (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for neurological disorders with significant unmet medical need, announced that it will resume trading on the Nasdaq Capital Market at the market open today, September 15, 2025, under the ticker symbol “SPRB” and...
Zur Nachricht
Spruce Biosciences
Charts & Research Termsheets Terminal
Permalink